Fauci Just Singled Out This Biotech Stock. Is It a Buy?
There are well over 100 separate COVID-19 vaccines in development at the moment. While many of the largest names in the healthcare industry have jumped at this opportunity to develop a vaccine, smaller, less-well-known companies are actually leading the way in this area.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), has singled out Moderna (NASDAQ: MRNA) and its COVID-19 vaccine candidate as being especially promising. What makes Moderna's COVID-19 vaccine so special, and is the company worth a spot in your investment portfolio?
Image source: Getty Images.
Source Fool.com
